Taysha Gene Therapies, Inc.

Biotechnology • Healthcare • Dallas, TX, United States • TSHA (NMS)

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

214 612 0000 3000 Pegasus Park Drive, Dallas, TX 75247, United States

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? - Yahoo Finance

Yahoo Finance • Dec 22

Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 4.8% - What's Next? - MarketBeat

MarketBeat • Jan 2

Taysha Gene Therapies stock hits 52-week high at $5.98 By Investing.com - Investing.com South Africa

Investing.com South Africa • Dec 24

Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy - Stocktwits

Stocktwits • Oct 2

Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades - Yahoo Finance

Yahoo Finance • Dec 22

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Taysha Gene Therapies, Inc. had layoffs?

No layoff events have been recorded for Taysha Gene Therapies, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Taysha Gene Therapies, Inc. have?

Taysha Gene Therapies, Inc. has approximately 73 employees.

What industry is Taysha Gene Therapies, Inc. in?

Taysha Gene Therapies, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Taysha Gene Therapies, Inc. a publicly traded company?

Yes, Taysha Gene Therapies, Inc. is publicly traded under the ticker symbol TSHA on the NMS. The company has a market capitalization of approximately $1.58 billion.

Where is Taysha Gene Therapies, Inc. headquartered?

Taysha Gene Therapies, Inc. is headquartered in Dallas, TX, United States at 3000 Pegasus Park Drive, Dallas, TX 75247, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.